ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Inflammation"

  • Abstract Number: 0592 • ACR Convergence 2022

    Autoantibodies Targeting Malondialdehyde-modifications Are Potential Mediators of Inflammation and Bone Loss in RA, Acting via Macrophage and Osteoclast Regulatory Pathways

    Jitong Sun1, Koji Sakuraba2, Akilan Krishnamurthy3, Xiaowei Zheng3, Marcelo Gomes Afonso3, Cheng Xu3, Bing Peng3, Per-Johan Jakobsson3, Marianne Engström3, Fredrik Wermeling3, Sergiu Catrina3, Caroline Grönwall3, Anca Catrina3 and Bence Réthi3, 1Karolinska Institutet, Solna, Sweden, 2Karolinska Institutet and Karolinska University Hospital, Fukuoka, Japan, 3Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Proteins subjected to post-translational modifications, such as citrullination, carbamylation, acetylation, malondialdehyde (MDA) or malondialdehyde/acetaldehyde (MDA/MAA) modification are targeted by autoantibodies in seropositive rheumatoid arthritis…
  • Abstract Number: 0831 • ACR Convergence 2022

    Management of Hepatic Sarcoidosis, a Retrospective Analysis of Patients at a University Hospital

    Kinza Muzaffar1, Sulman Hasan2, Sarwat umer2, Mohammad Alfrad Nobel Bhuiyan2, Kavya Vadlamudi2, Manush Sondhi2, Anusheh Ali1, Tabitha Muutu2 and Samina Hayat1, 1Louisiana State University, Shreveport, LA, 2LSU Health Shreveport, Shreveport, LA

    Background/Purpose: Sarcoidosis is a multisystem granulomatous disease which can affect the GI system in about 5-10% of cases, out of which 11-80% can have hepatic…
  • Abstract Number: 1326 • ACR Convergence 2022

    Impact of COVID-19 Severity on Bone Mineral Density, Sarcopenia and Physical Performance Among Older Adults Following Hospitalization: A Pilot Study

    Diego Cabrera1, Clara Wong2, Andrew Cohen3, Lauren Ferrante3, Alexandra Hajduk3 and Evelyn Hsieh1, 1Section of Rheumatology, Allergy and Immunology, Yale School of Medicine, New Haven, CT, 2Yale School of Public Health, New Haven, CT, 3Yale School of Medicine, New Haven, CT

    Background/Purpose: Altered bone mineral density (BMD), muscle mass and physical performance has been associated with adverse outcomes, however, the effect of COVID-19 on the musculoskeletal…
  • Abstract Number: 1687 • ACR Convergence 2022

    A Core Inflammation Program Conserved Across Human and Murine Neutrophils

    Nicolaj hackert1, Felix Radtke1, Tarik Exner1, Carsten Müller-Tidow1, Hanns-Martin Lorenz1, Peter Nigrovic2, Guido Wabnitz1 and Ricardo Grieshaber-Bouyer1, 1Heidelberg University Hospital, Heidelberg, Germany, 2Boston Children's Hospital, Boston, MA

    Background/Purpose: Neutrophils mediate a range of homeostatic and inflammatory processes and display substantial phenotypic and functional heterogeneity. While animal models enable important mechanistic discoveries, differences…
  • Abstract Number: 1972 • ACR Convergence 2022

    Comprehensive Investigation of Pain and Inflammation in Rheumatoid Arthritis from a Multidisciplinary Approach

    Lilla Tóth1, Gergely Orsi2, Krisztina Csókási3, Gábor Sütő4, Gábor Kumánovics5, Noémi Császár-Nagy6, Szabolcs Takács7, Eszter Szigedi8, Zsófia Nagy8, Zsolt Hodovány8, Lili Duzsik8, Zoltán Vidnyánszky9, József Kun10, Péter Urbán10, György Nagy11 and Zsuzsanna Helyes12, 1Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs, Hungary, 2MTA-PTE Clinical Neuroscience MR Research Group, Eötvös Loránd Research Network (ELKH); Department of Neurology, Medical School, University of Pecs, Pécs, Hungary, 3Institute of Psychology, Faculty of Humanities and Social Sciences, University of Pécs, Pécs, Hungary, 4Second Department of Medicine and Nephrology-Diabetes Centre, University of Pécs, Pécs, Hungary, 5Department of Rheumatology and Immunology, University of Pécs, Pécs, Hungary, 6National University of Public Services; Psychosomatic Outpatient Clinics, Budapest, Hungary, 7Department of Psychology, Karoly Gaspar University, Budapest, Hungary, 8Psychosomatic Outpatient Clinics, Budapest, Hungary, 9Brain Imaging Centre, Research Centre for Natural Sciences, Budapest, Hungary, 10Szentágothai Research Centre, Bioinformatics Research Group, Genomics and Bioinformatics Core Facility, University of Pécs, Pécs, Hungary, 11Department of Rheumatology and Clinical Immunology, Department of Internal Medicine and Oncology, Semmelweis University; Department of Genetics, Cell and Immunobiology, Semmelweis University; Heart and Vascular Centre, Semmelweis University, Budapest, Hungary, 12Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs; Szentágothai Research Centre and Centre for Neuroscience, University of Pécs, Pécs, Hungary

    Background/Purpose: Despite the therapeutic advances of rheumatoid arthritis (RA), optimal disease control cannot be achieved in the difficult-to-treat (D2T) RA population, leading to the persistence…
  • Abstract Number: 0384 • ACR Convergence 2022

    Inflammation Is Associated with Incident Hypertension in Patients with Axial Spondyloarthritis: A Longitudinal Cohort Study

    Jenny Lin Hong Shi1, Steven H Lam2, Ho So3, Edmund Li1, Tena Li1, Cheuk Chun Szeto1 and Lai-shan Tam1, 1The Chinese University of Hong Kong, Hong Kong, China, 2The Chinese university of Hong Kong, Hong Kong, Hong Kong, 3The Faculty of Medicine, CUHK, Hong Kong, Hong Kong

    Background/Purpose: In the general population, hypertension (HT) is reported as one of the most important risk and modifiable factors to develop CVD. It is well…
  • Abstract Number: 0596 • ACR Convergence 2022

    Neutrophil Extracellular Traps (NET) Trigger an Enhanced Pro-inflammatory Response in Macrophage Subpopulations in Rheumatoid Arthritis Patients via the Aryl Hydrocarbon Receptor (AhR) Pathway

    Dyhia Melbouci1, Sarra Seninet1, Marie-Christophe Boissier2, Elodie Segura3 and Patrice Decker1, 1University Sorbonne Paris Nord, Inserm UMR 1125, Li2P, Bobigny, France, 2INSERM UMR 1125, Sorbonne Paris Nord University,Rheumatology Dpt, APHP, GHUPSSD, Avicenne Hosp, Bobigny, France, 3U932 Inserm, Curie Institute, Paris, France

    Background/Purpose: Activated neutrophils (PMN) form neutrophil extracellular traps (NET), fibers of DNA and associated proteins expelled in the extracellular space. Increased NET formation has been…
  • Abstract Number: 0885 • ACR Convergence 2022

    Association Between Changes in Inflammatory Pathways Associated with a Reduction in CV Risk: Results from the LiiRA Study

    brittany weber1, Dana Weisenfeld1, Thany Seyok1, Elena Massarotti1, Selena Huang1, Derrick Todd1, Jonathan Coblyn1, michael weinblatt1, Tianrun Cai1, Kumar Dahal1, leanne BArrett1, Daniel Solomon1, Jorge Plutzky1, Marcy Bolster2, marcelo Dicarli1 and Katherine Liao1, 1Brigham and Women's Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, MA

    Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased cardiovascular (CV) risk. Coronary flow reserve (CFR) is a quantitative imaging biomarker of CV risk that…
  • Abstract Number: 1405 • ACR Convergence 2022

    In Contrast to Anti-CCP, Then MMP Degraded and Citrullinated Vimentin (VICM) Is Both a Diagnostic and Treatment Response Biomarker

    Patryk Drobinski1, Neel I. Nissen1, morten A. Karsdal2, Nicholas Willumsen2 and Anne-Christine Bay-Jensen2, 1University of Copenhagen, Copenhagen, Denmark, 2Nordic Bioscience, Herlev, Denmark

    Background/Purpose: The degree of protein citrullination and degradation by matrix metalloproteinases (MMP) play a central role in the pathology of rheumatoid arthritis (RA). Autoantibodies are…
  • Abstract Number: 1690 • ACR Convergence 2022

    Butyric Acid Suppresses Migration of Human Monocyte Derived Dendritc Cell by Inhibiting Actin Polymerization via mDia1 Inhibition

    Takumi Nagamoto1, takaichi okano2, Yoshikazu Fujikawa3, Yuzuru Yamamoto2, Hirotaka Yamada2, Yo Ueda2, Sho Sendo4 and Jun saegusa2, 1Kobe University, Kobe, Japan, 2Kobe University, Rheumatology, Kobe, Japan, 3Hyogo Prefectural Harima-Himeji General Medical Center, Himeji, Japan, 4University California, San Diego (UCSD), La Jolla, CA

    Background/Purpose: Butyric acid is known to improve chronic inflammation such as inflammatory bowel disease and arthritis. Dendritic cells activate in inflammatory condition, migrate to regional…
  • Abstract Number: 1977 • ACR Convergence 2022

    Tc99m Tilmanocept Imaging Predicts Clinical Response in Rheumatoid Arthritis Patients Beginning New Anti-TNFα Therapy

    Jonathan Graf1, Martin Jacobs2, Debbie Gladd-Foley3, Yelliann Ruiz-Irizarry4, Alan Kivitz5, Melvin Churchill6, Arash Kardan7, Mara Leach8, David Ralph8, Nicole Korczak8, Addison Hasselbach8, Bonnie Abbruzzese8, Rachael Hershey8, Beth Potter8, Jessica Fitzpatrick8, Aaron Thornton8, Michael Blue8 and Michael Rosol8, 1Ucsf, San Francisco, CA, 2Kettering Network Radiologists, Kettering, OH, 3Premier Rheumatology of Oklahoma, Tulsa, OK, 4Jackson Health System, Innovation Medical Research Center, Palmetto Bay, FL, 5Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, 6Arthritis Center of Nebraska, Bryan Health, Lincoln, NE, 7Baylor College of Medicine, Department of Radiology, Houston, TX, 8Navidea Biopharmaceuticals, Dublin, OH

    Background/Purpose: Effective and expeditious control of rheumatoid arthritis (RA) disease activity using a treat-to-target (T2T) strategy is crucial to prevent long term damage and disability.…
  • Abstract Number: 0404 • ACR Convergence 2022

    Site-Specific Responses of Joint and Entheses to Tofacitinib in Patients with Ankylosing Spondylitis: A Post Hoc Analysis of a Phase 3 Trial

    Raphael Micheroli1, Tim Killeen2, Hyejin Jo3, Kenneth Kwok3, Bassel Elzorkany4, Caroline Ospelt5, Adrian Ciurea6 and Michael Nissen7, 1University Hospital Zurich, Department of Rheumatology, Zürich, Switzerland, 2Pfizer Ltd, Tadworth, Switzerland, 3Pfizer Inc, New York, NY, 4Department of Rheumatology, Cairo University, Cairo, Egypt, 5Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 6University Hospital Zurich, Zürich, Switzerland, 7Hopitaux Universitaires de Genève, Geneva, Switzerland

    Background/Purpose: Sites of peripheral joint and enthesitis involvement in AS vary. Tofacitinib is an oral Janus kinase inhibitor for the treatment of AS. Differential site-specific…
  • Abstract Number: 0604 • ACR Convergence 2022

    Altered Metabolic State in Myeloid Precursors and Mature Cells Within Rheumatoid Arthritis

    Patricia Riedlova1, Luís Almeida2, Cecilia Ansalone3, Shatakshi Sood1, Bart Everts2 and Carl Goodyear1, 1University of Glasgow, Glasgow, Scotland, United Kingdom, 2Leiden University Medical Center, Leiden, Netherlands, 3UCSD and University of Glasgow, Glasgow, Scotland, United Kingdom

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterised by synovial inflammation and joint destruction. Prior research has revealed perturbation in the myeloid compartment of…
  • Abstract Number: 0903 • ACR Convergence 2022

    Plasma Inflammatory Protein Biomarkers May Predict Cardiovascular Events in Early Rheumatoid Arthritis

    Emil Rydell1, Lennart Jacobsson2 and Carl Turesson3, 1Lund University, Malmö, Sweden, 2Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden, 3Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden

    Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of cardiovascular disease (CVD). Systemic inflammation, driven by cytokines such as TNF, IL-6 and IL-17A,…
  • Abstract Number: 1487 • ACR Convergence 2022

    Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23

    James Krueger1, Kilian Eyerich2, Dennis McGonagle3, Carrie Greving4, Kacey Sachen4, Deepa Hammaker4, Phuc Bao4, Eilyn Lacy4, M. Merle Elloso5, Yevgeniya Orlovsky5, Iain B McInnes6 and Anne Fourie7, 1The Rockefeller University, New York, NY, 2Technical University, Munich, Germany / Karolinska Institute, Stockholm, Sweden, 3University of Leeds, Leeds, UK, Leeds, United Kingdom, 4Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, 5Janssen Research and Development, LLC, Spring House, PA, 6Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, 7Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, CA

    Background/Purpose: Clinically relevant differences between therapeutic antibodies against the same target may relate to their unique molecular attributes. Differences in therapeutic profiles across the domains…
  • « Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • …
  • 58
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology